Fusion Biopsy Market Size and Trends

The Global Fusion Biopsy Market is estimated to be valued at USD 791.1 Mn in 2025and is expected to reach USD 1,418.2 Mn by 2032 exhibiting a compound annual growth rate (CAGR) of 8.7% from 2025 to 2032.

Key Takeaways of the Fusion Biopsy Market:

By biopsy route, the transrectal segment is expected to contribute the highest share of the market with 53.1% in 2025.
By product, the equipment segment is expected to contribute the highest share of the market with 53.2% in 2025.
By application, the prostate cancer segment is expected to contribute the highest share of the market with 80.2% in 2025.
North America is expected to top the global market with 38.3% share, followed by Asia Pacific with 27.7% share in 2025.

Market Overview:

Advancements in biopsy devices and growing preference for minimally invasive procedures is expected to fuel the market growth during the forecast period. The market is witnessing positive trends with increasing adoption of fusion biopsy globally. Fusion biopsy helps overcome the issues with traditional biopsy methods by combining Magnetic Resonance Imaging (MRI) and ultrasound images to guide the biopsy needle to the suspected area, improving accuracy and maximizing tissue yields. As fusion biopsy provides real-time images to guide needle placement, it enables efficient sampling of tissues while reducing damage to nearby healthy tissues. This trend is expected to drive the demand for fusion biopsy devices.

Fusion Biopsy Market Concentration By Players

To learn more about this report, Request sample copy

Key Developments:

In September 2024, Koelis, a global leader and innovator in prostate care, announced a partnership with DeepHealth to enhance prostate cancer care through the integration of DeepHealth’s AI-powered prostate MRI software with Koelis' Trinity 3D Ultrasound Platform. This collaboration aims to streamline the prostate MRI reading process and enable seamless MRI-US fusion for biopsy and treatment. The Koelis Trinity system combines 3D ultrasound imaging with MRI-US fusion guidance, offering unique prostate motion tracking software.
In August 2024, Perineologic, a pioneer in transperineal prostate biopsy technology, announced a strategic investment from a group of private equity and hedge fund executives. This investment will support the company’s expansion and commercial sales efforts. CEO Mr. Matthew Allaway highlighted the endorsement of their vision and market leadership. With the new funding, Perineologic plans to accelerate market penetration of its Precision Point Transperineal Access System, known for its high cancer detection and low infection rates.
In April 2023, FUJIFILM Healthcare, a pioneer in diagnostic imaging and information systems, launched the ARIETTA 65 IntuitiveFusion, an MRI-US fusion prostate biopsy system on April 6, 2023. This system combines FUJIFILM's ARIETTA 65 ultrasound and MedCom's BiopSee software to enhance prostate biopsy efficiency. The integration of the device and software enables miniaturization and high operability, supporting more efficient and accurate MRI-US fusion prostate biopsies with various advanced functions.

Top Strategies Followed by Global Fusion Biopsy Market Players

Established players in the global fusion biopsy market focus heavily on research and development to drive innovation. Industry leaders such as Becton, Dickinson and Company invest over 5% of annual revenue into creating new fusion biopsy technologies. They leverage advances in robotics, imaging, and artificial intelligence to develop high-performance products.
Mid-sized companies concentrate on strategic partnerships and global expansion. Companies like Hologic partner with major hospitals and diagnostic centers to test and validate their fusion biopsy systems. Through such clinical collaborations, they improve product features to meet medical needs. Additionally, they grow international sales teams and distribution networks in key regions like Europe and Asia Pacific.
Smaller players focus on cost-effective solutions and niche specialization. They aim to make quality fusion biopsy affordable and accessible for budget-constrained healthcare facilities. For example, companies like MedCom target public hospitals and clinics in developing nations with economically priced devices. Some also collaborate with technology startups to incorporate features like automated biopsy reports and cloud connectivity in their products.

Emerging Startups - Fusion Biopsy Industry Ecosystem

Several startups are disrupting the fusion biopsy market through innovative technologies. Companies like Anthropic develop advanced AI algorithms to offer precision targeted biopsies. Their deep learning models can detect anomalies unnoticed on ultrasound and MRI scans, helping diagnose cancers sooner. Other startups offer smart biopsy gun platforms that provide real-time tissue sampling feedback using MEMS sensors and visual analytics. This enhances biopsy accuracy and minimizes repeat procedures.
More startups focus on sustainable innovations in fusion biopsy. BiopsyZen has developed biopsy devices using bio-based and recycled plastics, reducing medical waste. Their cartridges and needles are compostable to minimize environmental impact. PathAI applies computer vision to digitize biopsy samples, enabling virtual consultations and remote expert analysis. This promotes equitable access while reducing carbon footprint from transportation.
Many startups address niche clinical demands through partnerships. Companies work with top cancer centers and research universities to customize products for rare diseases. Others form consortiums to tackle global health issues like liver cancer diagnosis in underserved regions. Such collaborations accelerate the development and access of advanced yet affordable fusion biopsy technologies.